Suvretta Capital Management LLC Has $10.55 Million Holdings in Molecular Partners AG (NASDAQ:MOLN)

Suvretta Capital Management LLC increased its holdings in shares of Molecular Partners AG (NASDAQ:MOLN - Free Report) by 455.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,221,494 shares of the company's stock after buying an additional 1,821,494 shares during the quarter. Suvretta Capital Management LLC owned 5.50% of Molecular Partners worth $10,548,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, BVF Inc. IL increased its holdings in shares of Molecular Partners by 205.5% in the 4th quarter. BVF Inc. IL now owns 1,353,968 shares of the company's stock valued at $6,458,000 after purchasing an additional 910,747 shares during the period. 26.55% of the stock is currently owned by institutional investors and hedge funds.

Molecular Partners Trading Down 0.3%

NASDAQ MOLN traded down $0.01 on Tuesday, reaching $3.94. The stock had a trading volume of 3,868 shares, compared to its average volume of 20,967. Molecular Partners AG has a 1 year low of $3.36 and a 1 year high of $12.70. The business has a 50 day moving average price of $3.95 and a 200 day moving average price of $4.82. The company has a market capitalization of $159.08 million, a price-to-earnings ratio of -1.83 and a beta of 1.15.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.11). Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. On average, analysts anticipate that Molecular Partners AG will post -1.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Lifesci Capital initiated coverage on shares of Molecular Partners in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $12.00 target price for the company.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.